AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23252474 — intervention group
Group type: COMPARATOR
Intervention: Conventional care control
Number of subjects: 385
Study 21458989 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention (two weekly 6-h sessions of psycho-education and eight weekly 2-h sessions of group psychotherapy)
Number of subjects: 210
Study 21458989 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 210
Study 21458989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients using anti-depressive medication (both intervention and control groups)
Number of subjects: 210
Study 19231082 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic plus hypnosis
Number of subjects: 45
Study 19231082 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic
Number of subjects: 45
Study 19231082 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic plus attention
Number of subjects: 45
Study 19231082 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic plus hypnosis (for parents)
Number of subjects: 45
Study 17046804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Pelvic Floor Muscle Exercises (PFME) and support group
Number of subjects: 29
Study 17046804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 29
Study 14964334 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radio frequency energy therapy (PRFE)
Number of subjects: 40
Study 14964334 — intervention group
Group type: COMPARATOR
Intervention: PRFE placebo treatment (sham device)
Number of subjects: 40
Study 11117242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate peritoneal dialysis solution (Bic/Lac)
Number of subjects: 106
Study 11117242 — intervention group
Group type: COMPARATOR
Intervention: Standard lactate-buffered peritoneal dialysis solution (Lac)
Number of subjects: 106
Study 9393461 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' assessments of speech acceptability
Number of subjects: 20
Study 9393461 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' assessments of speech acceptability
Number of subjects: 20
Study 9393461 — intervention group
Group type: COMPARATOR
Intervention: Expert clinicians' assessments of speech acceptability
Number of subjects: 20
Study 9393461 — intervention group
Group type: COMPARATOR
Intervention: Naive peer raters' assessments
Number of subjects: 20
Study 7964828 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-resistance, continuous lumbar drainage (CRCLD)
Number of subjects: 15
Study 7964828 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunting (ventriculoperitoneal or lumboperitoneal)
Number of subjects: 15
Study 3111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etidronate disodium, 20 mg/kg/day
Number of subjects: 63
Study 3111705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3111705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etidronate disodium
Number of subjects: 63
Study 29254887 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 (40 mg twice a day)
Number of subjects: 32
Study 29254887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29254887 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931
Number of subjects: 32
Study 28818560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (mean ± SD of 10.46 ± 4.63 mg/24 h, n = 17)
Number of subjects: 34
Study 28818560 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (n = 17)
Number of subjects: 34
Study 26415296 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient vascular bypass during carotid endarterectomy (CEE)
Number of subjects: 45
Study 26415296 — intervention group
Group type: COMPARATOR
Intervention: No Bypass (Control group)
Number of subjects: 45
Study 24016511 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' ratings of HRQoL using Short Form-8
Number of subjects: 334
Study 24016511 — intervention group
Group type: COMPARATOR
Intervention: Patients' self-ratings of HRQoL using Short Form-12
Number of subjects: 334
Study 24016511 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 334
Study 24016511 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder
Number of subjects: 334
Study 24016511 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 334
Study 24016511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping disorder
Number of subjects: 334
Study 21173686 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline group (intra-articular injection of 20 ml normal saline)
Number of subjects: 40
Study 21173686 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral group (intra-articular injection of 20 ml normal saline)
Number of subjects: 40
Study 18498614 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% N,N‐diethyl‐3‐methylbenzamide (deet)
Number of subjects: 0
Study 18498614 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% and 20% (1S, 2'S) 2‐methylpiperidinyl‐3‐cyclohexene‐1‐carboxamide (SS220)
Number of subjects: 0
Study 18498614 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% and 20% 1‐methyl‐propyl‐2‐(hydroxyethyl)‐1‐piperidinecarboxylate (Bayrepel)
Number of subjects: 0
Study 16540115 — intervention group
Group type: EXPERIMENTAL
Intervention: Postevent information provided by an interviewer with varying levels of assertiveness (Study 1)
Number of subjects: 2
Study 16540115 — intervention group
Group type: EXPERIMENTAL
Intervention: Postevent information provided by a confederate with varying levels of assertiveness (Study 2)
Number of subjects: 2
Study 16540115 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying assertiveness in social influence
Number of subjects: 2
Study 12692110 — intervention group
Group type: COMPARATOR
Intervention: Total fruit consumption in the placebo arm
Number of subjects: 14120
Study 12692110 — intervention group
Group type: COMPARATOR
Intervention: Rosaceae fruit consumption in the placebo arm
Number of subjects: 14120
Study 12692110 — intervention group
Group type: COMPARATOR
Intervention: Cruciferae vegetables consumption in the placebo arm
Number of subjects: 14120
Study 12692110 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene and retinyl palmitate supplementation
Number of subjects: 14120
Study 10977118 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus bupivacaine (Group A)
Number of subjects: 60
Study 10977118 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (Group B)
Number of subjects: 60
Study 7567007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor
Number of subjects: 17
Study 7567007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2362952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 400 mg
Number of subjects: 24
Study 2362952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 800 mg
Number of subjects: 24
Study 2362952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 1200 mg
Number of subjects: 24
Study 2362952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (all dosages)
Number of subjects: 24
Study 450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy alone
Number of subjects: 189
Study 450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative uterine radium followed by hysterectomy
Number of subjects: 189
Study 450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy and postoperative vaginal radium
Number of subjects: 189
Study 450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade I lesions
Number of subjects: 189
Study 450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade II lesions
Number of subjects: 189
Study 31418851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment
Number of subjects: 377
Study 31418851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 377
Study 31418851 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke and infarct
Number of subjects: 377
Study 31418851 — intervention group
Group type: COMPARATOR
Intervention: Proven etiology group (rest)
Number of subjects: 377
Study 31418851 — intervention group
Group type: EXPERIMENTAL
Intervention: Down syndrome infants
Number of subjects: 377
Study 31418851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy in Down syndrome
Number of subjects: 377
Study 31418851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy in Down syndrome
Number of subjects: 377
Study 28887113 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg TCZ
Number of subjects: 37
Study 28887113 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg TCZ
Number of subjects: 37
Study 25623410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention
Number of subjects: 214
Study 25623410 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 214
Study 24324365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Training (AT) group
Number of subjects: 448
Study 24324365 — intervention group
Group type: COMPARATOR
Intervention: Passive Training (PT) group
Number of subjects: 448
Study 24324365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AT and PT)
Number of subjects: 448
Study 21546263 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal tibiofibular joint manipulation
Number of subjects: 43
Study 21546263 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal tibiofibular joint manipulation
Number of subjects: 43
Study 21546263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 21546263 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study 18340089 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Lay Health Advocate (CLHA) intervention
Number of subjects: 83
Study 18340089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83
Study 16872504 — intervention group
Group type: EXPERIMENTAL
Intervention: Training + Feedback
Number of subjects: 429
Study 16872504 — intervention group
Group type: COMPARATOR
Intervention: Feedback Only
Number of subjects: 429
Study 12849880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 59
Study 12849880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 59
Study 12849880 — intervention group
Group type: COMPARATOR
Intervention: Both antiepileptic drugs
Number of subjects: 59
Study 10853210 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind intubation via the ILM using a straight, silicone tube
Number of subjects: 150
Study 10853210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation with a Macintosh laryngoscope using a straight silicone tube
Number of subjects: 150
Study 10853210 — intervention group
Group type: COMPARATOR
Intervention: Intubation with a Macintosh laryngoscope using a polyvinyl chloride tube
Number of subjects: 150
Study 9226732 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/70 kg butorphanol, IV, in ice-cold water (2 degrees C)
Number of subjects: 13
Study 9226732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg morphine, IV, in ice-cold water (2 degrees C)
Number of subjects: 13
Study 9226732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg morphine, IV, in warm water (37 degrees C)
Number of subjects: 13
Study 9226732 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/70 kg butorphanol, IV, in warm water (37 degrees C)
Number of subjects: 13
Study 9226732 — intervention group
Group type: COMPARATOR
Intervention: Saline, IV, in both conditions
Number of subjects: 13
Study 8499682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmanate
Number of subjects: 450
Study 8499682 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum
Number of subjects: 450
Study 3432172 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 8
Study 3432172 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 8
Study 3432172 — intervention group
Group type: COMPARATOR
Intervention: salbutamol and fenoterol
Number of subjects: 8
Study 29294153 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1778
Study 29294153 — intervention group
Group type: COMPARATOR
Intervention: 2015 BTS guidelines
Number of subjects: 1778
Study 29294153 — intervention group
Group type: COMPARATOR
Intervention: 2017 Fleischner guidelines
Number of subjects: 1778
Study 27302744 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant Behavioural Treatment (OBT)
Number of subjects: 115
Study 27302744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment (CBT)
Number of subjects: 115
Study 27302744 — intervention group
Group type: COMPARATOR
Intervention: Whole-body infrared heat (IH)
Number of subjects: 115
Study 27302744 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls (CON)
Number of subjects: 115
Study 25031289 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg intramuscularly plus Azithromycin 2 g orally
Number of subjects: 401
Study 25031289 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg orally plus Azithromycin 2 g orally
Number of subjects: 401
Study 23057354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal reconstruction after laparoscopic tubal pregnancy operation
Number of subjects: 63
Study 23057354 — intervention group
Group type: COMPARATOR
Intervention: Simple laparoscopic tubal pregnancy operation
Number of subjects: 63
Study 20480839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal neurectomy group
Number of subjects: 240
Study 20480839 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliohypogastric neurectomy group
Number of subjects: 240
Study 20480839 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurectomies group
Number of subjects: 240
Study 20480839 — intervention group
Group type: COMPARATOR
Intervention: All-nerve preservation group
Number of subjects: 240
Study 20480839 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 18686759 — intervention group
Group type: EXPERIMENTAL
Intervention: Active trainees (compliant with training regimens)
Number of subjects: 0
Study 18686759 — intervention group
Group type: COMPARATOR
Intervention: Inactive trainees (non-compliant with training regimens)
Number of subjects: 0
Study 18686759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 15657157 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil, niacin, and cholestyramine
Number of subjects: 143
Study 15657157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 12687853 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 986
Study 12687853 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 986
Study 12687853 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 986
Study 12687853 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 986
Study 12687853 — intervention group
Group type: COMPARATOR
Intervention: Nonsurvivors
Number of subjects: 986
Study 12687853 — intervention group
Group type: COMPARATOR
Intervention: Victims of any mode of death
Number of subjects: 986
Study 12687853 — intervention group
Group type: COMPARATOR
Intervention: Patients with any mode of death
Number of subjects: 986
Study 10575071 — intervention group
Group type: EXPERIMENTAL
Intervention: Different movement amplitudes and types of holds
Number of subjects: 0
Study 8678278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg/kg with thiopentone 7 mg/kg i.v. (Group A)
Number of subjects: 43
Study 8678278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg with thiopentone 7 mg/kg i.v. (Group C)
Number of subjects: 43
Study 8678278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.25 mg/kg with propofol TIVA (Group B)
Number of subjects: 43
Study 8678278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg with propofol TIVA (Group D)
Number of subjects: 43
Study 8678278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg with thiopentone (Group E)
Number of subjects: 43
Study 8678278 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% 3 mg/kg given at the beginning of recovery phase
Number of subjects: 43
Study 1359745 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 800 mg b.i.d.
Number of subjects: 0
Study 1359745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2870809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 1% applied twice daily for 28 days
Number of subjects: 148
Study 2870809 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 148
Study 2870809 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 148
Study 29336265 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Plantavera gel
Number of subjects: 40
Study 29336265 — intervention group
Group type: COMPARATOR
Intervention: Topical Placebo gel
Number of subjects: 40
Study 28082115 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoCuff-assisted colonoscopy (EAC)
Number of subjects: 288
Study 28082115 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 288
Study 26079901 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP under general anesthesia
Number of subjects: 384
Study 26079901 — intervention group
Group type: COMPARATOR
Intervention: LLA using local anesthesia
Number of subjects: 384
Study 24655487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (salmon) providing 274 mg EPA + 671 mg DHA per day
Number of subjects: 33
Study 24655487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement providing 396 mg EPA + 250 mg DHA per day
Number of subjects: 33
Study 24655487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (salmon)
Number of subjects: 33
Study 24655487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement
Number of subjects: 33
Study 24655487 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (salmon and fish oil)
Number of subjects: 33
Study 22034636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 1248
Study 22034636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1248
Study 20451454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (18 g/m²)
Number of subjects: 232
Study 20451454 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cytarabine (2 g/m²)
Number of subjects: 232
Study 20451454 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction 2
Number of subjects: 232
Study 18504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) examination in patients with vascular and paralytic ileus
Number of subjects: 54
Study 18504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrogastrography (EGG) examination in patients with obstructive ileus
Number of subjects: 54
Study 18504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obstructive ileus and bradygastria
Number of subjects: 54
Study 18504369 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein concentration in patients with obstructive ileus
Number of subjects: 54
Study 15966088 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 312
Study 15966088 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (UKsurveil)
Number of subjects: 312
Study 12586512 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 'Fast' formulation (12 h)
Number of subjects: 18
Study 12586512 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 'Slow' formulation (24 h)
Number of subjects: 18
Study 12586512 — intervention group
Group type: COMPARATOR
Intervention: 2x15 mg immediate release tablets (12 h interval)
Number of subjects: 18
Study 10669909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of rifampicin and isoniazid
Number of subjects: 12
Study 10669909 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations of rifampicin and isoniazid
Number of subjects: 12
Study 8915147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination patch testing (two different sets of five patches each containing combinations of three or four allergens per patch)
Number of subjects: 137
Study 8915147 — intervention group
Group type: COMPARATOR
Intervention: Conventional patch testing (17 standard allergens applied individually)
Number of subjects: 137
Study 8915147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination patch testing (combination patches 1 and 2)
Number of subjects: 137
Study 8915147 — intervention group
Group type: COMPARATOR
Intervention: Conventional patch testing
Number of subjects: 137
Study 8915147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination patch testing
Number of subjects: 137
Study 1855691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of cimetidine 200 mg and alginic acid 500 mg, taken one tablet four times daily (increased to two tablets four times daily if response was unsatisfactory after six weeks)
Number of subjects: 312
Study 1855691 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage of cimetidine 400 mg four times daily
Number of subjects: 312
Study 1855691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of cimetidine 200 mg and alginic acid 500 mg
Number of subjects: 312
Study 6817188 — intervention group
Group type: EXPERIMENTAL
Intervention: Showering
Number of subjects: 82
Study 6817188 — intervention group
Group type: COMPARATOR
Intervention: Non-showering
Number of subjects: 82
Study 30726347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort A (n=2,143)
Number of subjects: 2796
Study 30726347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B (n=298)
Number of subjects: 2796
Study 30726347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort C (n=355)
Number of subjects: 2796
Study 30726347 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up (2010)
Number of subjects: 2796